Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach.

Critical reviews in immunology·2024
Same author

Advances in the Management of Neuroblastoma.

Critical reviews in eukaryotic gene expression·2023
Same author

Arboviruses: Transmission and Host Resistance.

Critical reviews in eukaryotic gene expression·2023
Same author

Human Oropharyngeal Candidiasis: From Etiology to Current Treatment.

Critical reviews in immunology·2023
Same author

Oncolytic Virotherapy: An Advanced Microbial Approach for the Management of Cancer.

Critical reviews in eukaryotic gene expression·2023
Same author

AIDS Dementia Complex: Neurotoxicity in AIDS Patients.

Critical reviews in eukaryotic gene expression·2023

Related Experiment Videos

Qadirvirtide.

Muhammad Imran Qadir1

  • 1College of Pharmacy, Government College University, Faisalabad, Pakistan. mrimranqadir@hotmail.com

Pakistan Journal of Pharmaceutical Sciences
|October 1, 2011
PubMed
Summary

Qadirvirtide is a novel peptide fusion inhibitor that prevents HIV entry into CD4 cells. This synthetic compound offers potential as a prophylactic or treatment for Acquired Immunodeficiency Syndrome (AIDS).

Area of Science:

  • Virology
  • Immunology
  • Drug Discovery

Background:

  • Acquired Immunodeficiency Syndrome (AIDS) is a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV).
  • Current HIV treatments involve antiretroviral therapy, but challenges like drug resistance and adherence persist.
  • Developing novel inhibitors targeting viral entry remains a critical area of research.

Purpose of the Study:

  • To investigate the potential of Qadirvirtide, a synthetic peptide, as a novel fusion inhibitor for HIV.
  • To elucidate the mechanism of action of Qadirvirtide in blocking HIV entry into host cells.

Main Methods:

  • Qadirvirtide was designed as a synthetic peptide comprising 36 amino acids.
  • Its mechanism involves binding to the HR1 region of the HIV gp41 protein.

Related Experiment Videos

  • This binding event inhibits the conformational changes necessary for viral fusion with the host cell membrane.

    • Main Results:

    • Qadirvirtide effectively acts as a fusion inhibitor.
    • It prevents the close approach of the HIV virus to the human CD4 cell membrane.
    • The fusion of the viral envelope with the human cell membrane is prohibited by Qadirvirtide.

    Conclusions:

    • Qadirvirtide demonstrates a promising mechanism for inhibiting HIV cell entry.
    • Its potential application in prophylaxis or treatment of AIDS warrants further investigation.
    • This peptide inhibitor represents a potential new avenue in the fight against HIV/AIDS.